Berobenatide for Obstructive Sleep Apnea

(VESPER-OSA 2 Trial)

This trial tests a study medicine called berobenatide to determine its effectiveness for people with obstructive sleep apnea (OSA), a condition where breathing stops during sleep. Researchers aim to assess the safety and effectiveness of berobenatide for adults with moderate to severe OSA who are overweight or obese, particularly those unable or unwilling to use a breathing machine (PAP therapy). Participants will receive either berobenatide or a placebo through a monthly injection. Suitable participants should be adults with moderate to severe OSA, have a higher body weight, and have not recently used a PAP machine. As a Phase 3 trial, this study is the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment for OSA.

Research shows that berobenatide is being developed to address conditions like obesity and obstructive sleep apnea. This small molecule peptide comes from Pfizer. Although specific safety data for berobenatide is not yet available, similar treatments provide some insight. For instance, drugs like tirzepatide, which resemble berobenatide, have proven safe for individuals with sleep apnea. These drugs are generally well-tolerated, with most side effects being mild to moderate.

Unlike the standard treatments for obstructive sleep apnea, which often involve continuous positive airway pressure (CPAP) machines or oral appliances, Berobenatide offers a new approach by being administered through a subcutaneous injection. This delivery method can be more convenient and less intrusive for patients. Researchers are excited about Berobenatide because it targets the underlying mechanisms of sleep apnea, potentially offering a more effective and comfortable solution compared to current options.

Research has shown that berobenatide, which participants in this trial may receive, might help treat obstructive sleep apnea (OSA). While tirzepatide has significantly lowered the Apnea-Hypopnea Index (AHI), aiding in weight loss and reducing blood pressure, studies suggest that berobenatide might offer similar benefits. This trial will specifically evaluate the effects of berobenatide on OSA.⁶⁷⁸⁹¹⁰